Pulse
NIFTY 5024,980.40+0.35%
SENSEX81,720.10+0.28%
NIFTY SHARIAH 254,850.15+0.42%
GOLD 24K (10g)₹75,420+0.38%
SILVER (1kg)₹88,400-0.12%
ACTIVE IPOS8 Open+38% GMP
TCS₹4,124.50+1.18%
INFY₹1,892.40+1.22%
USD/INR₹83.92-0.04%
NIFTY 5024,980.40+0.35%
SENSEX81,720.10+0.28%
NIFTY SHARIAH 254,850.15+0.42%
GOLD 24K (10g)₹75,420+0.38%
SILVER (1kg)₹88,400-0.12%
ACTIVE IPOS8 Open+38% GMP
TCS₹4,124.50+1.18%
INFY₹1,892.40+1.22%
USD/INR₹83.92-0.04%
Indo Us Bio-Tech Limited

Indo Us Bio-Tech Limited

NSE: INDOUS
Agricultural InputsBasic MaterialsSMALL CAPMCap ₹144.3 Cr
₹71.95₹0.31 (+0.43%)

Market Closed • NSE

Market cap₹144.3 Cr
Enterprise value₹175.0 Cr
P/E TTM12.62
P/B1.56
EPS TTM₹5.70
ROCE15.40%
D/E0.40
Dividend yield0.00%
Face value₹10.00
52W high₹159.00
52W low₹70.00
Price chart(1Y)
1Y Return:-20.56% (₹18.62)
H: ₹95.21L: ₹70
1W-0.14%
1M-9.31%
3M-17.64%
6M-32.69%
1Y-44.35%
Today at a glance

Day range

₹71.50₹74.97

52 week range

₹70.00₹159.00
Volume4.5K0.68x 20D avg
Free float50.00%-31.70% volume

Indo Us Bio-Tech Limited closed at INR71.95 (+0.43%) on volume 0.68x its 20-day average, trading 54.75% below its 52-week high.

Technical analysis
RSI (14)31.4Neutral (30–70)
MACDBEARISHBearish (Below signal)
ATR (14)₹3.96High
SMA 20₹75.60BEARISH
SMA 50₹78.71BEARISH
SMA 100₹84.07BEARISH
SMA 200₹99.57BEARISH
CPR bottom₹73.75
Pivot₹73.05
CPR top₹72.34
What changed recently?

2026-Q1

Q1 FY2026 Financial Results

PAT moved -34.2% QoQ

2024-12-03

DIVIDEND Announced

Interim Dividend - Rs 0.25 Per Share

Shariah audit
Methodology: AAOIFI Shariah Standard No. 21
PASS4/4 criteria
Shariah Compliant
CriteriaNumeratorDenominatorValueThresholdStatus
Interest-bearing debt ratio₹37.0 Cr₹144.3 Cr25.67%≤ 33%PASS
Non-halal income ratio–₹110.4 Cr0.00%≤ 5%PASS
Illiquid assets ratio₹127.0 Cr₹133.1 Cr95.40%≥ 20%PASS
Receivables ratio–₹133.1 Cr—≤ 49%PASS
Valuation & sector context
MetricCompanySector
P/E12.6221.90
Forward P/E——
P/B1.562.20
EV/EBITDA—18.00
PEG—1.00
Earnings yield7.904.60
Growth & profitability
RevenuePAT
FY21PAT margin 12.40%
FY22PAT margin 10.20%
FY23PAT margin 11.70%
FY24PAT margin 11.30%
FY25PAT margin 15.70%
FY26PAT margin 11.90%

Revenue and PAT bars use independent scales to make their year-on-year direction readable.

Revenue CAGR 3Y+21.40%
Revenue CAGR 5Y+22.90%
PAT CAGR 3Y+21.90%
PAT CAGR 5Y+21.80%
Operating margin11.57%
Net margin10.17%
Financial health & cash flow
Net debt₹30.9 CrModerate
Interest coverage7.20xEBIT / interest
CFO / PAT-0.24x3Y average
Net debt / EBITDA—Leverage
Operating cash flow₹-1258.1 Lakh
Capital expenditure–
Free cash flow₹-1498.9 Lakh
Financial statements

Complete reported financial history · Values use the company's reporting currency

Hover over the chart for exact reported values. Percentage lines use the right-hand axis.

Fundamental scorecard
Overall83/100
Valuation75/100
Profitability80/100
Financial health95/100

A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.

Strengths, risks & investment thesis

Strengths

Strong Capital Efficiency: ROCE stands at 15.4%

Low Debt Profile: Debt-to-Equity is comfortable at 0.40x

Attractive Valuation: P/E of 12.6x trades below sector historical averages

Risks

Subject to cyclical raw material and macro industry pressures

Bull case

Market Leadership: Established operational scale in Agricultural Inputs.

Bear case

Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.

Flip condition

Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.

Shareholding pattern
Quarterly ownership historyLatest valid period · September 2025

Ownership distribution

Sept 2025Latest holding

Category trends

Hover over a period for exact holdings

80%53%27%0%Sept 2024Dec 2024Jun 2025Sept 2025
0.01%Institutional holding
31.70%Public holding
4Periods available
0.00%Promoter pledged
4.69KShareholders
Corporate Action

Complete dividend, bonus, split, rights and other action history

Record dateCorporate actionInformationAnnouncement dateEx-date
03 Dec 2024Dividend₹0.25 / share—03 Dec 2024
Delivery participation

Traded volume and delivery percentage across the latest 20 sessions

Average delivery (20D)57.47%-11.97% latest vs average
Highest delivery95.32%on 29 Sept
Average volume (20D)6.6KTrading-session average
Conviction trendWeakening-11.97% latest reading
Traded volumeDelivery %
Peer comparison

Compare valuation, latest quarterly performance and year-on-year growth

8 companies
Company nameMarket cap ₹ CrP/E ratioDividend yield %Quarterly sales ₹ CrProfit after tax ₹ CrSales growth %Profit growth %
UltraTech Cement Limited
UltraTech Cement LimitedULTRACEMCO
Open analysis
₹3.21L37.592.21%₹25,799.47₹2,982.76+11.86%+20.17%
JSW Steel Limited
JSW Steel LimitedJSWSTEEL
Open analysis
₹2.97L12.050.59%₹47,364.00₹4,651.00+11.55%+112.96%
Hindustan Zinc Limited
Hindustan Zinc LimitedHINDZINC
Open analysis
₹2.28L13.372.07%₹13,687.00₹5,425.00+77.22%+146.14%
Asian Paints Limited
Asian Paints LimitedASIANPAINT
Open analysis
₹2.24L46.941.17%₹10,541.94₹1,539.25+17.94%+39.96%
Tata Steel Limited
Tata Steel LimitedTATASTEEL
Open analysis
₹2.19L19.832.27%₹60,794.00₹2,385.00+14.32%+18.83%
Hindalco Industries Limited
Hindalco Industries LimitedHINDALCO
Open analysis
₹2.02L12.320.56%₹84,825.00₹7,013.00+32.06%+75.15%
Grasim Industries Limited
Grasim Industries LimitedGRASIM
Open analysis
₹1.98L34.820.35%₹11,794.71₹246.65-70.60%-82.61%
Solar Industries India Limited
Solar Industries India LimitedSOLARINDS
Open analysis
₹1.81L90.930.06%₹3,668.00₹666.00+70.29%+88.67%
About Indo Us Bio-Tech Limited
Indo Us Bio-Tech Limited

Incorporated in 2004, Indo US Bio-Tech Ltd is engaged in production and processing of commercial and vegetable seeds[1]

IndiaBasic Materials

Questions investors ask
Is Indo Us Bio-Tech Limited Shariah compliant?

Indo Us Bio-Tech Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (25.67%) complies with AAOIFI threshold (≤ 33%).

What is Indo Us Bio-Tech Limited's current valuation relative to peers?

Indo Us Bio-Tech Limited trades at a P/E of 12.6x compared to the sector median of 21.9x, and a Price-to-Book of 1.6x.

Is the company financially healthy?

The company has a Debt-to-Equity ratio of 0.40x. Interest coverage is 7.2x.

What are the historical revenue and profit growth rates?

Over the past 5 years, revenue compounded at 22.9% while net profit growth averaged 21.8%.

Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.

Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.